Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CSCSCI.TOthis companyCOSCIENS Biopharma Inc.	CA$8.60	-0.21×	0.57×	0.29×	0.32×	-4514.4%	35.3%	-139.3%	-138.1%	-274.8%	-59.0%	-428.0%	0.56×	0.55×	-62.15×	3.18×	0.0%	5	0.24	2	C+
APTX.TOApotex Health Corp.	CA$34.78	16.77×	-11.21×	1.79×	10.66×	345.4%	55.6%	22.5%	10.7%	-67.0%	17.6%	7.3%	-6.31×	3.8×	3.24×	1.5×	17.7%	—	—	—	—
BLCO.TOBausch + Lomb Corporation	CA$28.83	-16.74×	0.94×	1.18×	18.09×	-58.7%	54.8%	3.7%	-7.1%	-5.6%	1.5%	-1.1%	0.83×	8.17×	0.45×	1.55×	0.0%	5	1.13	1	C-
BLCOBausch + Lomb Corporation	$20.38	-16.75×	0.94×	1.18×	20.62×	-65.1%	54.8%	3.7%	-7.1%	-5.6%	1.5%	-1.1%	0.83×	9.32×	0.44×	1.55×	0.0%	5	1.05	1	C-
ABCLAbCellera Biologics Inc.	$12.39	-6.98×	1.06×	13.6×	-6.97×	-113.4%	61.6%	-289.0%	-194.9%	-15.1%	-13.8%	-17.0%	0.15×	-0.1×	0×	11.32×	0.0%	3	5.23	2	C
XENEXenon Pharmaceuticals Inc.	$39.61	-10.28×	6.11×	473.62×	-9.82×	-93.5%	66.1%	-4974.3%	-4612.1%	-59.5%	-39.6%	-7.9%	0.01×	0.56×	0×	13.42×	0.0%	2	39.15	2	C
Peer median	—	-10.28×	0.94×	1.79×	10.66×	-65.1%	55.6%	3.7%	-7.1%	-15.1%	1.5%	-1.1%	0.15×	3.8×	0.44×	1.55×	0.0%	4	3.18	2	—